ARTICLE | Finance

Strengthening the (Immuno)core

How Immunocore attracted the biotech industry's biggest-ever series A

July 20, 2015 7:00 AM UTC

The moral of the biggest series A round in the history of biotech is that playing nicely with checkpoint inhibitors and other cancer therapies can create significant value.

Immunocore Ltd. is the case in point, as the developer of T cell receptor (TCR)-based therapies raised $320 million on Thursday. The round was led by new investors Woodford Investment Management, Malin Corp. plc and Eli Lilly and Co. (NYSE:LLY). ...